vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and WYNDHAM HOTELS & RESORTS, INC. (WH). Click either name above to swap in a different company.

CLOVER HEALTH INVESTMENTS, CORP. is the larger business by last-quarter revenue ($487.7M vs $334.0M, roughly 1.5× WYNDHAM HOTELS & RESORTS, INC.). CLOVER HEALTH INVESTMENTS, CORP. runs the higher net margin — -10.1% vs -18.0%, a 7.9% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (44.7% vs -76.3%). WYNDHAM HOTELS & RESORTS, INC. produced more free cash flow last quarter ($168.0M vs $-69.0M). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (18.6% CAGR vs -4.6%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

Wyndham Hotels & Resorts, Inc., is an American hospitality company based in Parsippany, New Jersey, United States. It describes itself as the largest hotel franchisor in the world, with 9,100 locations.

CLOV vs WH — Head-to-Head

Bigger by revenue
CLOV
CLOV
1.5× larger
CLOV
$487.7M
$334.0M
WH
Growing faster (revenue YoY)
CLOV
CLOV
+121.0% gap
CLOV
44.7%
-76.3%
WH
Higher net margin
CLOV
CLOV
7.9% more per $
CLOV
-10.1%
-18.0%
WH
More free cash flow
WH
WH
$237.0M more FCF
WH
$168.0M
$-69.0M
CLOV
Faster 2-yr revenue CAGR
CLOV
CLOV
Annualised
CLOV
18.6%
-4.6%
WH

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CLOV
CLOV
WH
WH
Revenue
$487.7M
$334.0M
Net Profit
$-49.3M
$-60.0M
Gross Margin
Operating Margin
-10.1%
Net Margin
-10.1%
-18.0%
Revenue YoY
44.7%
-76.3%
Net Profit YoY
-123.2%
-170.6%
EPS (diluted)
$-0.80

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
WH
WH
Q1 26
$334.0M
Q4 25
$487.7M
$334.0M
Q3 25
$496.6M
$382.0M
Q2 25
$477.6M
$397.0M
Q1 25
$462.3M
$316.0M
Q4 24
$337.0M
$336.0M
Q3 24
$331.0M
$396.0M
Q2 24
$356.3M
$367.0M
Net Profit
CLOV
CLOV
WH
WH
Q1 26
$-60.0M
Q4 25
$-49.3M
$-60.0M
Q3 25
$-24.4M
$105.0M
Q2 25
$-10.6M
$87.0M
Q1 25
$-1.3M
$61.0M
Q4 24
$-22.1M
$85.0M
Q3 24
$-9.2M
$102.0M
Q2 24
$7.4M
$86.0M
Gross Margin
CLOV
CLOV
WH
WH
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
24.5%
Q2 24
30.3%
Operating Margin
CLOV
CLOV
WH
WH
Q1 26
Q4 25
-10.1%
-11.4%
Q3 25
-4.9%
46.6%
Q2 25
-2.2%
37.8%
Q1 25
-0.3%
35.4%
Q4 24
-6.4%
38.4%
Q3 24
-2.7%
43.2%
Q2 24
2.0%
39.5%
Net Margin
CLOV
CLOV
WH
WH
Q1 26
-18.0%
Q4 25
-10.1%
-18.0%
Q3 25
-4.9%
27.5%
Q2 25
-2.2%
21.9%
Q1 25
-0.3%
19.3%
Q4 24
-6.6%
25.3%
Q3 24
-2.8%
25.8%
Q2 24
2.1%
23.4%
EPS (diluted)
CLOV
CLOV
WH
WH
Q1 26
$-0.80
Q4 25
$-0.77
Q3 25
$1.36
Q2 25
$1.13
Q1 25
$0.78
Q4 24
$1.06
Q3 24
$1.29
Q2 24
$1.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
WH
WH
Cash + ST InvestmentsLiquidity on hand
$78.3M
$64.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$308.7M
$468.0M
Total Assets
$541.0M
$4.2B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
WH
WH
Q1 26
$64.0M
Q4 25
$78.3M
$64.0M
Q3 25
$70.0M
Q2 25
$50.0M
Q1 25
$48.0M
Q4 24
$194.5M
$103.0M
Q3 24
$288.0M
$72.0M
Q2 24
$254.8M
$70.0M
Total Debt
CLOV
CLOV
WH
WH
Q1 26
Q4 25
$2.5B
Q3 25
$2.6B
Q2 25
$2.5B
Q1 25
$2.5B
Q4 24
$2.4B
Q3 24
$2.4B
Q2 24
$2.4B
Stockholders' Equity
CLOV
CLOV
WH
WH
Q1 26
$468.0M
Q4 25
$308.7M
$468.0M
Q3 25
$340.9M
$583.0M
Q2 25
$344.2M
$570.0M
Q1 25
$336.1M
$579.0M
Q4 24
$341.1M
$650.0M
Q3 24
$342.2M
$583.0M
Q2 24
$324.9M
$623.0M
Total Assets
CLOV
CLOV
WH
WH
Q1 26
$4.2B
Q4 25
$541.0M
$4.2B
Q3 25
$559.7M
$4.3B
Q2 25
$575.0M
$4.3B
Q1 25
$583.7M
$4.2B
Q4 24
$580.7M
$4.2B
Q3 24
$653.0M
$4.2B
Q2 24
$674.2M
$4.2B
Debt / Equity
CLOV
CLOV
WH
WH
Q1 26
Q4 25
5.37×
Q3 25
4.43×
Q2 25
4.44×
Q1 25
4.29×
Q4 24
3.72×
Q3 24
4.19×
Q2 24
3.83×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
WH
WH
Operating Cash FlowLast quarter
$-66.9M
$367.0M
Free Cash FlowOCF − Capex
$-69.0M
$168.0M
FCF MarginFCF / Revenue
-14.1%
50.3%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-69.2M
$437.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
WH
WH
Q1 26
$367.0M
Q4 25
$-66.9M
$152.0M
Q3 25
$12.1M
$86.0M
Q2 25
$5.4M
$70.0M
Q1 25
$-16.3M
$59.0M
Q4 24
$34.8M
$134.0M
Q3 24
$50.0M
$79.0M
Q2 24
$44.8M
$1.0M
Free Cash Flow
CLOV
CLOV
WH
WH
Q1 26
$168.0M
Q4 25
$-69.0M
$136.0M
Q3 25
$11.4M
$75.0M
Q2 25
$4.8M
$58.0M
Q1 25
$-16.5M
$52.0M
Q4 24
$33.3M
$109.0M
Q3 24
$49.6M
$71.0M
Q2 24
$44.4M
$-6.0M
FCF Margin
CLOV
CLOV
WH
WH
Q1 26
50.3%
Q4 25
-14.1%
40.7%
Q3 25
2.3%
19.6%
Q2 25
1.0%
14.6%
Q1 25
-3.6%
16.5%
Q4 24
9.9%
32.4%
Q3 24
15.0%
17.9%
Q2 24
12.5%
-1.6%
Capex Intensity
CLOV
CLOV
WH
WH
Q1 26
Q4 25
0.4%
4.8%
Q3 25
0.1%
2.9%
Q2 25
0.1%
3.0%
Q1 25
0.0%
2.2%
Q4 24
0.5%
7.4%
Q3 24
0.1%
2.0%
Q2 24
0.1%
1.9%
Cash Conversion
CLOV
CLOV
WH
WH
Q1 26
Q4 25
Q3 25
0.82×
Q2 25
0.80×
Q1 25
0.97×
Q4 24
1.58×
Q3 24
0.77×
Q2 24
6.04×
0.01×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLOV
CLOV

Segment breakdown not available.

WH
WH

Fee-related and other revenues$334.0M100%
Management and other fees$2.0M1%

Related Comparisons